Unicycive to present at H.C. Wainwright investor conference

Unicycive Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15, 2026, with CEO Shalabh Gupta, M.D., taking the stage at 11 a.m. ET. The appearance gives investors another update point for the kidney disease biotech as it advances lead candidate oxylanthanum carbonate and second program UNI-494.

Why it matters: - Unicycive Therapeutics gets a public platform to update investors on its kidney disease pipeline. - The presentation may help keep attention on the company ahead of future development milestones for its lead and second investigational treatments.

What happened: - Unicycive Therapeutics said Chief Executive Officer Shalabh Gupta, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference. - The presentation is scheduled for Tuesday, Sept. 15, 2026, at 11 a.m. ET. - The company said a live and archived webcast will be available on the Unicycive website in the Investors section under Events and Presentations. - Unicycive Therapeutics is a clinical-stage biotechnology company focused on therapies for patients with kidney disease. - The company is a B2i Digital Featured Company, with an in-depth profile available here.

The details: - Unicycive’s lead investigational treatment is oxylanthanum carbonate, a phosphate-binding agent being developed for hyperphosphatemia in patients with chronic kidney disease on dialysis. - The company’s second investigational treatment is UNI-494, which is intended for conditions related to acute kidney injury. - UNI-494 has received orphan drug designation from the FDA for prevention of delayed graft function in kidney transplant patients. - UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers. - More information about the company is available on Unicycive’s website.

Between the lines: - Conference presentations often serve as a visibility check-in for small biotech companies with clinical pipelines. - The timing suggests Unicycive is using the event to keep investors focused on both its lead program and its earlier-stage backup asset.

What's next: - Investors can watch for the Sept. 15 presentation and any webcast materials posted afterward. - The company may use the conference to frame the next steps for oxylanthanum carbonate and UNI-494.